Date: May 7, 2026
Subject: Advanced Management and Surgical Evolution in Severe Tricuspid Regurgitation
Expert Panel: Dr. Rick Nishimura and Dr. Michael Mack
Introduction: The "Forgotten Valve" Reclaimed
For decades, the tricuspid valve was relegated to the periphery of cardiovascular medicine, often labeled the "forgotten valve." Historically, severe tricuspid regurgitation (TR) was viewed primarily as a secondary consequence of left-sided heart disease—a condition to be monitored rather than aggressively treated. However, as of 2026, the clinical landscape has shifted dramatically. In a recent installment of the Heart Valve Matters podcast series, preeminent cardiologists Dr. Rick Nishimura and Dr. Michael Mack engaged in a comprehensive discussion regarding the transition of TR management from a conservative "watch-and-wait" approach to a sophisticated, interventional, and surgical discipline.
This article synthesizes their discussion, mapping the evolution of clinical evaluation, the timing of surgical intervention, and the implications of new technologies on patient outcomes.
1. Main Facts: The Clinical Challenge of TR
Tricuspid regurgitation is characterized by the failure of the tricuspid valve to close properly, leading to backflow of blood into the right atrium. While mild forms are common and often benign, severe TR is associated with significant morbidity, including heart failure, renal impairment, and systemic venous congestion.
The core of the challenge, as highlighted by Dr. Nishimura, lies in the timing. Historically, surgeons and cardiologists were hesitant to operate on the tricuspid valve due to the high mortality rates associated with reoperative surgery. Patients presenting with isolated TR were often only referred for surgery once they reached a state of irreversible right-sided heart failure—a point where the window for meaningful clinical improvement had already closed.
Dr. Mack emphasized that the current paradigm shift is driven by a better understanding of right ventricular (RV) hemodynamics and the realization that prolonged volume overload leads to structural remodeling of the RV that is, in many cases, irreversible.
2. Chronology: From Neglect to Intervention
To understand the current state of TR management, one must look at the historical trajectory of the field:
- The Era of Neglect (Pre-2015): TR was largely ignored in the context of left-sided valve surgery. Unless a patient was undergoing primary valve replacement, the tricuspid valve was rarely touched, leading to high rates of late-stage heart failure.
- The Advent of Imaging (2015–2020): Advances in 3D echocardiography and cardiac MRI allowed for more precise grading of TR severity. Clinicians began to quantify the "effective regurgitant orifice area" (EROA) and recognized the prognostic power of RV dilation.
- The Transcatheter Revolution (2020–2025): The introduction of transcatheter edge-to-edge repair (TEER) and other valve-repair devices transformed the treatment of "inoperable" patients. This period saw the first large-scale clinical trials validating that fixing the valve before irreversible RV damage occurs significantly improves quality of life.
- The Current Standard (2026): We are currently in the era of "Multidisciplinary Heart Teams." The consensus now favors early intervention, utilizing a combination of surgical expertise and interventional techniques, tailored to the patient’s specific anatomical and physiological profile.
3. Supporting Data: Why Timing Matters
The data presented in the discussion underscores a critical truth: The RV is a sensitive organ. Once an RV begins to fail, the prognosis drops precipitously.
Hemodynamic Remodeling
Dr. Nishimura notes that clinicians must track the "right-sided pressure profile." Using data derived from hemodynamic studies, the panel highlighted that patients with a high degree of venous congestion—evidenced by liver function changes and renal dysfunction—are already in a late stage of the disease.
The Surgical Threshold
Data from recent surgical registries suggest that when patients undergo surgery before the onset of severe RV dysfunction, the survival rates are comparable to, or better than, those who continue on medical management. The "Goldilocks" window for intervention—early enough to avoid permanent myocardial scarring, but late enough to ensure the patient actually requires the procedure—is the current primary focus of clinical research.
4. Official Responses and Expert Consensus
Both Dr. Nishimura and Dr. Michael Mack advocate for a "Heart Team" approach. This is not merely a suggestion but a requirement for modern cardiovascular centers.
- The Role of the Surgeon: Dr. Mack clarifies that surgery remains the gold standard for many patients, particularly those with significant annular dilation or underlying leaflet pathology that is not well-suited for transcatheter approaches. He notes that modern surgical techniques have become less invasive and more focused on durability.
- The Role of the Interventionalist: The panel acknowledges that the rise of transcatheter options has expanded the treatable population. Many elderly patients, who previously would have been denied surgery due to high surgical risk, are now eligible for less invasive repair, significantly improving their functional capacity.
- The Role of Medical Management: Both experts stress that medical therapy—specifically the optimization of diuretics and newer agents addressing neurohormonal pathways—is not a replacement for intervention but a bridge to it.
5. Implications for Future Practice
The shift in TR management has several profound implications for the cardiovascular community:
Training and Education
The "Tricuspid Training Series" highlights the need for specialized training in right-heart imaging. Cardiologists must be proficient not just in looking at the mitral or aortic valves, but in understanding the complex geometry of the tricuspid annulus.
Healthcare Resource Allocation
As more patients are identified with severe TR, hospitals will need to dedicate more resources to dedicated Valve Clinics. The cost-effectiveness of early intervention is high when one considers the reduction in heart failure-related hospitalizations, which are a major burden on the healthcare system.
Patient Selection
The most critical implication is the move toward personalized medicine. No two TR cases are identical. Some patients have primary pathology (e.g., rheumatic, endocarditis), while others have secondary, functional TR. The treatment pathway must be individualized based on the patient’s age, comorbidities, and the specific anatomy of the valve.
Conclusion: A New Horizon
The conversation between Dr. Nishimura and Dr. Mack serves as a clarion call for the medical community to abandon the outdated notion that TR is a benign or untreatable condition. By integrating advanced imaging, early surgical or interventional referral, and a multidisciplinary team approach, physicians can provide significant relief to a patient population that was once left to suffer from the debilitating effects of systemic venous congestion.
As the field moves into the latter half of the decade, the focus will undoubtedly turn toward long-term durability data for transcatheter devices and the refinement of surgical techniques that minimize recovery time. The "forgotten valve" has indeed been reclaimed, and with it, the potential to restore the quality of life for thousands of patients worldwide.
For those interested in exploring this topic further, the full audio recording of the discussion is available on the TCTMD Heart Valve Matters portal. Clinicians are encouraged to review the provided documentation on echocardiographic criteria for severe TR and to participate in upcoming training sessions focused on interventional valve repair.
